Biohaven Ltd. Common Shares (BHVN) closed at $13.80 on November 16, 2026, down 0.1% from the previous close, on volume of 1,550,232 shares (30-day average 3,083,537).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Seagull With Put Spread | 18-Dec-2610 P : 12.5 P : 15 C | 1,647 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Biohaven Presents Development Programs at Jefferies Healthcare Conference
TipRanks (Mon, 16-Nov 7:04 AM ET)
PRNewswire (Thu, 5-Nov 7:30 AM ET)
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
PRNewswire (Thu, 29-Oct 4:03 PM ET)
PRNewswire (Mon, 26-Oct 7:31 AM ET)
PRNewswire (Thu, 8-Oct 4:01 AM ET)
PRNewswire (Mon, 28-Sep 7:31 AM ET)
PRNewswire (Fri, 11-Sep 6:28 PM ET)
PRNewswire (Wed, 26-Aug 2:37 AM ET)
PRNewswire (Tue, 25-Aug 4:43 PM ET)
Market Chameleon (Mon, 29-Jun 4:36 AM ET)
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Biohaven Ltd. Common Shares trades on the NYSE stock market under the symbol BHVN.
As of November 17, 2026, BHVN stock price declined to $13.42 with 658,543 million shares trading.
BHVN has a beta of 1.26, meaning it tends to be more sensitive to market movements. BHVN has a correlation of 0.05 to the broad based SPY ETF.
BHVN has a market cap of $2.03 billion. This is considered a Mid Cap stock.
Last quarter Biohaven Ltd. Common Shares reported $0 in Revenue and -$.73 earnings per share. This fell short of revenue expectation by $-110 million and missed earnings estimates by -$.70.
In the last 3 years, BHVN traded as high as $62.21 and as low as $7.48.
The top ETF exchange traded funds that BHVN belongs to (by Net Assets): XBI, IWM, VXF, IWO, IBB.
BHVN has outperformed the market in the last year with a return of +61.7%, while the SPY ETF gained +10.0%. However, in the most recent history, BHVN shares have underperformed the stock market with its stock returning -8.3% in the last 3 month period and -11.5% for the last 2 week period, while SPY has returned -5.6% and -2.8%, respectively.
BHVN support price is $13.06 and resistance is $14.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHVN shares will trade within this expected range on the day.